VEGFA and Hypertension: In the recent systemic review, Semeniuk-Wojtas et al. [99], included 48 eligible phase III and IV prospective clinical trials, meta-analyses and retrospective studies describing the AEs in a form of hypertension or other nephrotoxicity in patients received anti-VEGF drugs.